


# NVP DPP 728

**Alternative Names:** DPP 728

Latest Information Update: 14 May 2002



## At a glance

## At a glance

- **Originator** Novartis
- **Class** Antihyperglycaemics; Nitriles; Pyrrolidines; Small molecules
- **Mechanism of Action** CD26 antigen inhibitors
- **Orphan Drug Status**

**Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.**

No

- **On Fast track**

**Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.**

No

- **New Molecular Entity** Yes

## Highest Development Phases

- **Discontinued** Type 2 diabetes mellitus


## Most Recent Events

- **14 May 2002** A clinical study has been added to the pharmacodynamics section
- **04 Dec 2001** Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
- **05 Apr 2001** A preclinical study has been added to the Diabetes pharmacodynamics section

# P 3298

**Alternative Names:** P-32-98; P32/98

**Latest Information Update:** 22 Feb 2008



## At a glance

## At a glance

- **Originator** Probiodrug
- **Class** Antihyperglycaemics; Thiazolidines
- **Mechanism of Action** CD26 antigen inhibitors

- **Orphan Drug Status**

**Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.**

No

- **On Fast track**

**Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.**

No

- **New Molecular Entity** Yes

## Highest Development Phases

- **Discontinued** Type 2 diabetes mellitus


## Most Recent Events

- **04 Dec 2002** Probiodrug has granted a non-exclusive licence to Ferring and its sublicensee, Ortho-McNeil Pharmaceuticals, for the inhibitors of dipeptidyl peptidase IV for diabetes and obesity
- **06 Apr 2001** Phase-II clinical trials for Type-2 diabetes mellitus in Germany (PO)
- **20 Feb 2001** A study has been added to the adverse events section

# Denagliptin

**Alternative Names:** 823093; GW 823093; GW823093C; Redona

Latest Information Update: 29 May 2015



## At a glance

## At a glance

- **Originator** GlaxoSmithKline
- **Class** Antihyperglycaemics; Aromatic amino acids; Pyrrolidines; Small molecules
- **Mechanism of Action** Dipeptidyl-peptidase and tripeptidyl-peptidase inhibitors

- **Orphan Drug Status**

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

- **On Fast track**

Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

No

- **New Molecular Entity** Yes

## Highest Development Phases

- **Discontinued** Type 2 diabetes mellitus

## Most Recent Events

- **20 Apr 2015** GlaxoSmithKline withdraws a phase II/III trial in Type-2 diabetes mellitus in USA and Finland due to the cancellation of the trial (NCT00387972; EudraCT2006-002157-79)
- **08 Nov 2006** Suspended - Phase-III for Type-2 diabetes mellitus in United Kingdom (PO)
- **28 Jul 2006** Phase-II/III clinical trials in Type-2 diabetes mellitus in United Kingdom (PO)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.